RxDoctor Payments Data

Richard Chu, DO

Ophthalmology · Fort Worth, TXNPI 1164728044

Payments from drug & device makers

$211,375in general payments, 2019–2025

Across 520 payments — averaging $406.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon Research LLC$166K
  • Sight Sciences, Inc.$22K
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$10K
  • Glaukos Corporation$3K
  • Alcon$3K
  • Johnson & Johnson Surgical Vision, Inc.$3K
  • plus $4K from 23 others

What the payments were for

  • Consulting fees$8,47519%
  • Speaking & faculty fees$24,60054%
  • Travel & lodging$1,7604%
  • Food & beverage$10,42923%
  • Education$800%
  • Gifts$190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$211,375 in reported general payments places this provider in the 90th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$260,711
Medicare patients
352
Services billed
1,776

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MieboPerfluorohexyloctane/Pf22$16,900
Prednisolone Acetate292$15,068
RestasisCyclosporine15$13,754
XiidraLifitegrast12$11,493
BesivanceBesifloxacin Hcl37$8,392
LumiganBimatoprost14$8,376
MoxifloxacinMoxifloxacin Hcl274$7,684
Lotemax SmLoteprednol Etabonate27$6,812
VyzultaLatanoprostene Bunod21$6,679
Ketorolac Tromethamine211$5,389
TobradexTobramycin/Dexamethasone20$5,325
ProlensaBromfenac Sodium14$4,843
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol39$4,771
Cyclosporine19$3,959
Brimonidine Tartrate34$3,036

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Miebo, Xiidra, Vyzulta$650$35,07255 claims
AbbVieRestasis, Lumigan$580$22,13029 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCBesivance, Lotemax Sm, Prolensa$10,150$20,04878 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →